www.fdanews.com/articles/73900-osi-pharmaceuticals-grants-license-to-merck
OSI PHARMACEUTICALS GRANTS LICENSE TO MERCK
June 30, 2005
OSI Pharmaceuticals has announced that its diabetes and obesity business unit (OSI) Prosidion, has granted Merck a worldwide, non-exclusive license under U.S. Patent No. 6,890,898 and foreign equivalents thereof which claim combination therapy comprising administration of a DPIV inhibitor and another therapeutic agent for the treatment of Type 2 diabetes and related indications. OSI will receive upfront, milestone and royalty payments. Additional financial terms were not disclosed.
BioSpace